93595-52-9

Upstream product

• 344442-67-7 1-(2-amino-5-chlorobenzoyl)-4,4-dimethylsemicarbazide 
• 344757-56-8 C₁₂H₁₇ClN₄O₂ 
• 5584-15-6 5-chloroanthranilic acid hydrazide 
• 530-62-1 1,1'-carbonyldiimidazole 
• 5202-89-1 4-chlorobenzenesulfonyl chloride 
• 183244-16-8 5-chloro-2-nitrobenzohydrazide 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 4743-17-3 5-Chloroisatoic anhydride 
• 635-21-2 5-chloroanthranilic acid 
• 93595-34-7 1-(2-amino-5-chlorobenzoyl)-4,4-diphenylsemicarbazide 

Relevant academic research and scientific papers

ARYLCARBOXAMIDES AND USES THEREOF

The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic diseases such as scleroderma; lung disease, such as pulmonary fibrosis including idiopathic pulmonary fibrosis (IPF); heart disease, such as heart failure due to ischaemic heart disease, valvular heart disease and hypertensive heart disease, diabetic cardiomyopathy and hypertension; liver disease, such as cirrhosis of the liver; and kidney disease, such as progressive kidney disease glomerulonephritis and diabetic nephropathy; and eye disease such as diabetic retinopathy; skin or subcutaneous scarring, such as keloids, adhesions, hypertrophic scarring or cosmetic scarring; or as an adjuvant or anti-fibrotic in pancreatic cancer to increase chemotherapeutic drug penetration by reducing the density of the connective tissue stroma.

Synthesis and Pharmacological Evaluation of Fenamate Analogues: 1,3,4-Oxadiazol-2-ones and 1,3,4-Oxadiazole-2-thiones

A series of fenamate pyridyl or quinolinyl analogues of 1,3,4-oxadiazol-2-ones 5a-d and 6a-r, and 1,3,4-oxadiazole-2-thiones 5e-g and 6s-v, respectively, have been synthesized and evaluated for their analgesic (hot-plate), antiinflammatory (carrageenin induced rat's paw edema) and ulcerogenic effects as well as plasma prostaglandin E2 (PGE 2) level. The highest analgesic activity was achieved with compound 5a (0.5, 0.6, 0.7 mmol/kg b.wt.) in respect with mefenamic acid (0.4 mmol/kg b.wt.). Compounds 6h, 61 and 5g showed 93, 88 and 84% inhibition, respectively on the carrageenan-induced rat's paw edema at dose level of 0.1mmol/kg, b.wt, compared with 58% inhibition of mefenamic acid (0.2mmol/kg b.wt.). Moreover, the highest inhibitory activity on plasma PGE2 level was displayed also with 6h, 61 and 5g (71, 70, 68.5% respectively, 0.1mmol/kg b.wt.) compared with indomethacin (60%, 0.01 mmol/kg b.wt.) as a reference drug. In addition 6i, 6k, 6p, 6r, 6t and 6v were devoid of any ulcerogenicity.

The Preparation of 5-(2-Aminophenyl)-1,3,4-oxadiazole-2(3H)-one and Its Rearrangement to 3-Amino-2,4(1H,3H)-quinazolinedione

When anthranilic acid hydrazide is reacted with 1,1'-carbonyldiimidazole in THF 5-(2-aminophenyl)-1,3,4-oxadiazole-2(3H)-one (4) is formed.It can also be prepared from 1-o-aminobenzoyl-4,4-dimethylsemicarbazide which eliminates methylamine when boiled with DMF.On heating the 5-(2-aminophenyl)-1,3,4-oxadiazole above its melting point it rearranges to 3-amino-2,4(1H,3H)-quinazolinedione (5). - Keywords: 3,4-Dihydro-1H-1,3,4-benzotriazepine-2,5-dione; Oxadiazoles